Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Kymera Therapeutics Q2 EPS $(0.95) Misses $(0.84) Estimate, Sales $11.476M Miss $21.214M Estimate

Author: Benzinga Newsdesk | August 11, 2025 06:04am
Kymera Therapeutics (NASDAQ:KYMR) reported quarterly losses of $(0.95) per share which missed the analyst consensus estimate of $(0.84) by 12.83 percent. This is a 63.79 percent decrease over losses of $(0.58) per share from the same period last year. The company reported quarterly sales of $11.476 million which missed the analyst consensus estimate of $21.214 million by 45.90 percent. This is a 55.26 percent decrease over sales of $25.650 million the same period last year.

Posted In: KYMR


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist